Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lennartsson, J.
Right arrow Articles by Shivakrupa, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lennartsson, J.
Right arrow Articles by Shivakrupa, R.

Stem Cells 2005;23:16-43 www.StemCells.com
© 2005 AlphaMed Press

CONCISE REVIEW

Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit

Johan Lennartsson, Tanya Jelacic, Diana Linnekin, R. Shivakrupa

Basic Research Laboratory, Center for Cancer Research, National Cancer Institute–Frederick, Frederick, Maryland, USA

Key Words. Kit • Signal transduction • Hematopoiesis • Oncogene • Cancer

Correspondence: Johan Lennartsson, Ph.D., Ludwig Institute for Cancer Research, Box 595, Biomedical Center, SE-751 24 Uppsala, Sweden. Telephone: 46-18-160406; Fax: 46-18-160420; e-mail: Johan.Lennartsson{at}LICR.uu.se

Kit is a receptor tyrosine kinase (RTK) that binds stem cell factor. This receptor ligand combination is important for normal hematopoiesis, as well as pigmentation, gut function, and reproduction. Structurally, Kit has both an extracellular and intracellular region. Theintra-cellular region is comprised of a juxtamembrane domain (JMD), a kinase domain, a kinase insert, and a carboxyl tail. Inappropriate expression or activation of Kit is associated with a variety of diseases in humans. Activating mutations in Kit have been identified primarily in the JMD and the second part of the kinase domain and have been associated with gastrointestinal stromal cell tumors and mastocytosis, respectively. There are also reports of activating mutations in some forms of germ cell tumors and core binding factor leukemias. Since the cloning of the Kit ligand in the early 1990s, there has been an explosion of information relating to the mechanism of action of normal forms of Kit as well as activated mutants. This is important because understanding this RTK at the biochemical level could assist in the development of therapeutics to treat primary and secondary defects in the tissues that require Kit. Furthermore, understanding the mechanisms mediating transformation of cells by activated Kit mutants will help in the design of interventions for human disease associated with these mutations. The objective of this review is to summarize what is known about normal and oncogenic forms of Kit. We will place particular emphasis on recent developments in understanding the mechanisms of action of normal and activated forms of this RTK and its association with human disease, particularly in hematopoietic cells.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
L. A. Samayawardhena and C. J. Pallen
Protein-tyrosine Phosphatase {alpha} Regulates Stem Cell Factor-dependent c-Kit Activation and Migration of Mast Cells
J. Biol. Chem., October 24, 2008; 283(43): 29175 - 29185.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
R. A.J. Oostendorp, S. Gilfillan, A. Parmar, M. Schiemann, S. Marz, M. Niemeyer, S. Schill, E. Hammerschmid, V. R. Jacobs, C. Peschel, et al.
Oncostatin M-Mediated Regulation of KIT-Ligand-Induced Extracellular Signal-Regulated Kinase Signaling Maintains Hematopoietic Repopulating Activity of Lin-CD34+CD133+ Cord Blood Cells
Stem Cells, August 1, 2008; 26(8): 2164 - 2172.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. S.M. Smalley, R. Contractor, T. K. Nguyen, M. Xiao, R. Edwards, V. Muthusamy, A. J. King, K. T. Flaherty, M. Bosenberg, M. Herlyn, et al.
Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression
Cancer Res., July 15, 2008; 68(14): 5743 - 5752.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Jahn, E. Leifheit, S. Gooch, S. Sindhu, and K. Weinberg
Lipid rafts are required for Kit survival and proliferation signals
Blood, September 15, 2007; 110(6): 1739 - 1747.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Guida, S. Anaganti, L. Provitera, R. Gedrich, E. Sullivan, S. M. Wilhelm, M. Santoro, and F. Carlomagno
Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor {beta} Gatekeeper Mutants
Clin. Cancer Res., June 1, 2007; 13(11): 3363 - 3369.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
V. Dolgachev, M. Thomas, A. Berlin, and N. W. Lukacs
Stem cell factor-mediated activation pathways promote murine eosinophil CCL6 production and survival
J. Leukoc. Biol., April 1, 2007; 81(4): 1111 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. G. Roberts, A. F. Odell, E. M. Byrnes, R. M. Baleato, R. Griffith, A. B. Lyons, and L. K. Ashman
Resistance to c-KIT kinase inhibitors conferred by V654A mutation
Mol. Cancer Ther., March 1, 2007; 6(3): 1159 - 1166.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Pan, A. Quintas-Cardama, H. M. Kantarjian, C. Akin, T. Manshouri, P. Lamb, J. E. Cortes, A. Tefferi, F. J. Giles, and S. Verstovsek
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation
Blood, January 1, 2007; 109(1): 315 - 322.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J.J. Galan, M. De Felici, B. Buch, M.C. Rivero, A. Segura, J.L. Royo, N. Cruz, L.M. Real, and A. Ruiz
Association of genetic markers within the KIT and KITLG genes with human male infertility
Hum. Reprod., December 1, 2006; 21(12): 3185 - 3192.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Yu, J. Luo, W. Yang, Y. Wang, M. Mizuki, Y. Kanakura, P. Besmer, B. G. Neel, and H. Gu
The Scaffolding Adapter Gab2, via Shp-2, Regulates Kit-evoked Mast Cell Proliferation by Activating the Rac/JNK Pathway
J. Biol. Chem., September 29, 2006; 281(39): 28615 - 28626.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Paschka, G. Marcucci, A. S. Ruppert, K. Mrozek, H. Chen, R. A. Kittles, T. Vukosavljevic, D. Perrotti, J. W. Vardiman, A. J. Carroll, et al.
Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study
J. Clin. Oncol., August 20, 2006; 24(24): 3904 - 3911.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. C. Goldman, L. K. Berg, M. C. Heinrich, and J. L. Christian
Ectodermally derived steel/stem cell factor functions non-cell autonomously during primitive erythropoiesis in Xenopus
Blood, April 15, 2006; 107(8): 3114 - 3121.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Z.-j. Ye, Y. Kluger, Z. Lian, and S. M. Weissman
Two types of precursor cells in a multipotential hematopoietic cell line
PNAS, December 20, 2005; 102(51): 18461 - 18466.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 2005 by AlphaMed Press.